COMPUTED DESCRIPTORS
| Molecular Weight | 3339.7 g/mol |
|---|---|
| XLogP3 | -13.4 |
| Hydrogen Bond Donor Count | 49 |
| Hydrogen Bond Acceptor Count | 50 |
| Rotatable Bond Count | 109 |
| Exact Mass | 3338.7128803 g/mol |
| Monoisotopic Mass | 3337.7095254 g/mol |
| Topological Polar Surface Area | 1390 Ų |
| Heavy Atom Count | 237 |
| Formal Charge | 0 |
| Complexity | 7810 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 29 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently-Bonded Unit Count | 1 |
| Compound Is Canonicalized | Yes |
PRODUCT INTRODUCTION
description
Taspoglutide is a pharmaceutical drug, a glucagon-like peptide-1 agonist (GLP-1 agonist), under investigation for treatment of type 2 diabetes being codeveloped by Ipsen and Roche. In September 2010 Roche halted Phase III clinical trials due to incidences of serious hypersensitivity reactions and gastrointestinal side effects. As of May 2013 no new trials had been registered.